10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research

What happened: 10x Genomics ($TXG) announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies in solid tumors and blood cancers, its first clinical research initiative in hematologic malignancies. Key numbers: TXG fell 5.6% at yesterday's close. Why it matters: The collaboration could expand TXG's technology into clinically relevant applications and, if research succeeds, lift demand among cancer centers and pharmaceutical researchers. It also supports its planned CLIA-certified laboratory. Market: +1.8% by next close ($74.65 on Oct 9), -12.6% YTD

10x Genomics ($TXG) announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies in solid tumors and blood cancers, its first clinical research initiative in hematologic malignancies.

The collaboration could expand TXG's technology into clinically relevant applications and, if research succeeds, lift demand among cancer centers and pharmaceutical researchers. It also supports its planned CLIA-certified laboratory. Market: +1.8% by next close ($74.65 on Oct 9), -12.6% YTD